MapLight Therapeutics (MPLT) Liabilities and Shareholders Equity (2024 - 2025)
MapLight Therapeutics recorded quarterly Liabilities and Shareholders Equity of $479.5 million in Q4 2025, up 86.42% quarter-over-quarter from $257.2 million in Q3 2025, and up 250.22% year-over-year from $136.9 million in Q4 2024.
MapLight Therapeutics' Liabilities and Shareholders Equity history runs 2 years deep, the most recent figure standing at $479.5 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity rose 250.22% year-over-year to $479.5 million; the TTM figure through Dec 2025 stood at $873.6 million (changed N/A YoY), while the FY2025 annual figure was $479.5 million, up 250.22% from the prior year.
- Liabilities and Shareholders Equity came in at $479.5 million for Q4 2025 at MapLight Therapeutics, up from $257.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $479.5 million in Q4 2025 to a low of $136.9 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 479.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 479.51 Mn |
| Sep 30, 2025 | 257.22 Mn |
| Dec 31, 2024 | 136.92 Mn |